learn HMI-115
much-hyped research compound targeting prolactin receptor in scalp
Search
forResearch
5 / 1000+ results
research Adverse Cutaneous Reactions to the New Second-Generation Tyrosine Kinase Inhibitors (Dasatinib, Nilotinib) in Chronic Myeloid Leukemia
Many patients on new leukemia drugs had mild to moderate skin reactions.
research Comparative Transcriptome Profiling Provides New Insights Into Mechanisms of Androgenetic Alopecia Progression
AGA progression involves increased lipid synthesis, electron transport, and hair follicle miniaturization.
research Regeneration of Hair and Other Skin Appendages: A Microenvironment-Centric View
The microenvironment, especially mechanical forces, plays a crucial role in hair growth and could lead to new treatments for hair loss.
Community Join
5 / 175 resultscommunity HLT Megathread on HMI-115 (key takeaways in comments)
HMI-115, a newly discovered hair loss treatment that could potentially be effective for those with diffuse thinning and telogen effluvium. It is based on prolactin receptor antagonist signaling and has already undergone Phase I trials in women, with potential commercialization by 2027.